Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound
All patients undergoing video-assisted thoracoscopic (VATS) resection of lung cancer will receive standard therapy including lobectomy or sub-lobar resection and mediastinal lymph node dissection. After completion of the standard of care, intraoperative ultrasound will be used to evaluate lymph node stations for the presence of any missed lymph nodes with particular focus on lymph nodes which may appear pathologic on ultrasound evaluation. Data will be reviewed for rates of pathologic upstaging, and sensitivity and specificity of ultrasound as an additional diagnostic tool in the operating room will be evaluated. It is hypothesized that Intra-operative thoracoscopic ultrasound following standard video-assisted thoracoscopic (VATS) dissection will increase the rate of pathologically staged in N2 nodes in non-small cell lung cancer patients undergoing definitive surgical resection.
Checked against the public recordLast updated Nov 7, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Joel Thompson, PhD
- Interventions being studied
- Device: Intraoperative ultrasound
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: Age ≥18 years. Eastern Cooperative Oncology Group performance status ≤2 (Karnofsky ≥60%, see Appendix A). Life expectancy of greater than 3 months Patients be able to undergo VATS resection as defined below: * Preoperative Forced Expiratory Volume at one second ≥ 40% predicted * OR * Post-operative predicted Forced Expiratory Volume at one second ≥ 0.8 l * Hg ≥ 8.0 * No evidence of coronary ischemia on stress evaluation Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Patients with surgery for a prior ipsilateral lung cancer Patients with known brain metastases Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. (Patients with HIV are not excluded from this study)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Kentucky, Markey Cancer CenterLexington, Kentucky
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 7, 2018. Always confirm current availability with the study team.